Wrodzony obrzęk naczynioruchowy u dzieci

• Authors: Ewa Czarnobilska , Małgorzata Bulanda

Title variants

EN

Hereditary angioedema in children

• Languages of publication: PL EN

Abstracts

PL

Wrodzony obrzęk naczynioruchowy (Hereditary angioedema, HAE) u dzieci jest rzadką chorobą charakteryzującą się epizodami obrzęku tkanki podskórnej lub podśluzowej bez bąbla pokrzywkowego i świą- du, ustępującymi spontanicznie w ciągu 1-5 dni, opornymi na działanie leków przeciwhistaminowych i glikokortykosteroidów. Średni wiek rozwoju objawów to 10 lat, a 40% dotkniętych chorobą osób przeżywa swój pierwszy atak w wieku poniżej 5 lat. HAE jest najczęściej zwią- zany z dziedzicznym zmniejszeniem stężenia lub dysfunkcją inhibitora C1 (C1-INH). Powoduje to aktywację układu dopełniacza i akumulację bradykininy prowadzącą do obrzęku tkanek. W diagnostyce HAE istotny jest wywiad, morfologiczne cechy obrzęku i wyniki badań dodatkowych (stężenie i aktywność C1-INH, stężenie składowej C4 dopełniacza). Ostateczna diagnoza wymaga co najmniej dwóch zgodnych wyników badań przesiewowych, przy czym drugie z nich powinno zostać przeprowadzone po 1. r.ż. W rodzinach ze znaną mutacją można wykonać badania genetyczne. Badania pokazują częste opóźnienia w diagnozie, które mają negatywny wpływ na jakość życia pacjentów. Obecnie w Polsce refundowane są dwa preparaty do stosowania w leczeniu HAE w populacji pediatrycznej - koncentrat C1 inhibitora: Berinert (bez ograniczeń wiekowych) i rekombinowany koncentrat C1 inhibitora: Ruconest (od 13. r.ż.).

EN

Hereditary angioedema (HAE) is a rare disease characterized by episodes of subcutaneous or submucosal oedema, without urticaria and itching, spontaneously resolving within 1-5 days, resistant to antihistamines and glucocorticosteroids. The average age of development of symptoms is 10 years, and 40% of affected individuals experience their first attack under the age of 5. HAE is most commonly associated with inherited decrease of the concentration of C1 inhibitor (C1 INH) or dysfunction of C1 INH. This activates the complement and causes bradykinin accumulation leading to tissue edema. Diagnosis of HAE includes an interview, the morphological characteristics of swelling and the results of additional tests (concentration and activity of C1 INH, concentration of complement component 4). The final diagnosis requires at least two consistent results of screening tests, the second one should be carried out after the first year of age. Genetic tests can be performed in families with a known mutation. Research on HAE reveal frequent delays in the diagnosis, which have a negative impact on quality of life. At present, 2 preparations used in treatment of HAE in pediatric population are refunded in Poland: concentrate of C1 INH: Berinert (no age restrictions) and recombinant concentrate of C1 INH: Ruconest (from 13 years of age).

Keywords

EN

C1-inhibitor; dzieci; dziedziczny obrzęk naczynioruchowy

Discipline

• MEDICINE: MEDICINE

• Publisher: Oficyna Wydawnicza Mediton
• Journal: Alergia Astma Immunologia - przegląd kliniczny
• Year: 2018
• Volume: 23
• Issue: 4
• Pages: 193-198

Contributors

author

Ewa Czarnobilska

author

Małgorzata Bulanda

References

• 1. Obtułowicz K. Dziedziczny obrzęk naczynioruchowy. (w) Alergia, choroby alergiczne, astma. T. II. Fal A (red.). Medycyna Praktyczna, Kraków 2011: 355-62.
• 2. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-9.
• 3. Bafunno V, Firinu D, D’Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018; 141: 1009-17.
• 4. Bork K, Wulff K, Steinm€uller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73: 442-50.
• 5. Caldwell JR, Ruddy S, Schur PH, et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1972; 1: 39-52.
• 6. Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976; 48: 567-80.
• 7. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/ EAACI guideline for the management of hereditary angioedema - The 2017 revision and update. Allergy 2018; 73: 1575-96.
• 8. Germenis AE, Speletas M. Genetics of hereditary angioedema revisited. Clin Rev Allergy Immunol 2016; 51: 170-82.
• 9. Lopez-Lera A, Garrido S, Roche O, et al. SERPING1 mutations in 59 families with hereditary angioedema. Mol Immunol 2011; 49: 18- 27.
• 10. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147-54.
• 11. Donaldson VH, Rosen FS. Action of complement in hereditary angioneurotic edema: the role of C’1-esterase. J Clin Invest 1964; 43: 2204-13.
• 12. Kaplan AP, Joseph K. Complement, kinins, and hereditary angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol 2016; 51: 207-15.
• 13. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
• 14. Donaldson VH. Kinin formation in hereditary angioneurotic edema (HANE) plasma. Int Arch Allergy Appl Immunol 1973; 45: 206-9.
• 15. Whalley ET, Amure YO, Lye RH. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 433-7.
• 16. Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106: 546-50.
• 17. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-17.
• 18. Read N, Lim E, Tarzi MD, et al. Paediatric Hereditary Angioedema: A survey of UK service provision and patient experience. Clin Exp Immunol 2014; 178: 483-8.
• 19. MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol 2014; 25: 420-7.
• 20. Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017; 72: 300-13.
• 21. Obtułowicz K, Czarnobilska E, Klimaszewska-Rembiasz M i wsp. Wrodzony obrzęk naczynioruchowy u dzieci. Alergol Immunol 2013; 10: 15-18.
• 22. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-54.
• 23. Martinez-Saguer I, Graff J, Rusicke E, et al. Does early clinical manifestation of hereditary angioedema (HAE) influence the clinical course of the disease? J Allergy Clin Immunol 2013; 131: 30.
• 24. Christiansen SC, Davis DK, Castaldo AJ, et al. Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr (Phila) 2016; 55: 935-42.
• 25. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992; 71: 206-15.
• 26. Obtułowicz K. Wrodzony obrzęk naczynioruchowy. Napady obrzę- ku groźne dla życia u dorosłych i u dzieci. Alergol Immunol 2012; 9: 220-2.
• 27. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-7.
• 28. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107: 529-37.
• 29. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-74.
• 30. Nielsen EW, Johansen HT, Holt J, et al. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35: 184-7.
• 31. Aabom A, Andersen KE, Fagerberg C, et al. Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema. Orphanet J Rare Dis 2017; 12: 55-65.
• 32. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2014; 10: 50-68.
• 33. Spath PJ, Wuthrich B. Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms. Recenti Prog Med 1990; 81: 513-31.
• 34. Speletas M, Szilagyi A, Psarros F, et al. Hereditary angioedema: molecular and clinical differences among European populations. J Allergy Clin Immunol 2015; 135: 570-3.
• 35. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-31.
• 36. Nanda MK, Singh U, Wilmot J, et al. A cross-sectional questionnaire assessing patient and physician use of short-term prophylaxis for hereditary angioedema. Ann Allergy Asthma Immunol 2014; 113: 198-203.
• 37. Wahn V, Aberer W, Eberl W, et al. Hereditary angioedema (HAE) in children and adolescents – a consensus on therapeutic strategies. Eur J Pediatr 2012; 171: 1339-48.
• 38. Frank MM, Zuraw B, Banerji A, et al. Management of children with hereditary angioedema due to C1 inhibitor deficiency. Pediatrics 2016; 138: e20160575-20160586.
• 39. Bowen T. Hereditary angioedema consensus 2010. Allergy Asthma Clin Immunol 2010; 6: 13-15.
• 40. Farkas H, Csuka D, Zotter Z, et al. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol 2013; 131: 579-82.
• 41. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010; 6: 18-28.
• 42. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: 713-22.

• Document Type: article